These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7919576)

  • 1. Intravenous ciprofloxacin dosing in a morbidly obese patient.
    Caldwell JB; Nilsen AK
    Ann Pharmacother; 1994 Jun; 28(6):806. PubMed ID: 7919576
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of cephalexin failure rates in morbidly obese patients with cellulitis.
    Kaufman KR; Thurber KM; O'Meara JG; Langworthy DR; Kashiwagi DT
    J Clin Pharm Ther; 2016 Aug; 41(4):409-13. PubMed ID: 27193482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patient.
    Luque S; Grau S; Valle M; Colino CI; Ferrer A
    J Antimicrob Chemother; 2011 Jul; 66(7):1653-4. PubMed ID: 21474480
    [No Abstract]   [Full Text] [Related]  

  • 4. Ciprofloxacin for soft tissue infections.
    Wood MJ; Logan MN
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():159-64. PubMed ID: 3804904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciprofloxacin treatment of acute infections in immunocompromised host.
    Nemes G; Heuser Y; Stolle D; Piroth HD; Nemes P
    J Chemother; 1989 Jul; 1(4 Suppl):722-3. PubMed ID: 16312607
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravenous and oral ciprofloxacin in the therapy of serious infections.
    Gibert CL; Seiler M; Joe L; Smith MA; Gordin F
    Diagn Microbiol Infect Dis; 1990; 13(2):173-6. PubMed ID: 2369811
    [No Abstract]   [Full Text] [Related]  

  • 7. Ciprofloxacin: major advances in intravenous and oral quinolone therapy. Proceedings of a symposium. April 28 to 29, 1989, Naples, Florida.
    Am J Med; 1989 Nov; 87(5A):1S-287S. PubMed ID: 2589353
    [No Abstract]   [Full Text] [Related]  

  • 8. Double-blind comparison of ciprofloxacin with cefotaxime in the treatment of skin and skin structure infections.
    Pérez-Ruvalcaba JA; Quintero-Pérez NP; Morales-Reyes JJ; Huitrón-Ramírez JA; Rodríguez-Chagollán JJ; Rodríguez-Noriega E
    Am J Med; 1987 Apr; 82(4A):242-6. PubMed ID: 3555042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study.
    van Rhee KP; Smit C; Wasmann RE; van der Linden PD; Wiezer R; Van Dongen EPA; Krekels EHJ; Brüggemann RJM; Knibbe CAJ
    Clin Pharmacokinet; 2022 Aug; 61(8):1167-1175. PubMed ID: 35641862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative, double-blind study of intravenous ciprofloxacin and intravenous ceftazidime in serious infection.
    Ramirez-Ronda CH; Saavedra S; Rivera-Vazquez CR
    Am J Med; 1989 Nov; 87(5A):195S-197S. PubMed ID: 2686423
    [No Abstract]   [Full Text] [Related]  

  • 11. [Ciprofloxacin by the intravenous route in the treatment of respiratory infections].
    Mangiarotti P; Manara G; Bianchi L; Piccioni PD; Grassi C
    G Ital Chemioter; 1989; 36(1-3):89-94. PubMed ID: 2488917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature.
    Myzienski AE; Lutz MF; Smythe MA
    Pharmacotherapy; 2010 Mar; 30(3):324. PubMed ID: 20180615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying optimal initial infusion rates for unfractionated heparin in morbidly obese patients.
    Riney JN; Hollands JM; Smith JR; Deal EN
    Ann Pharmacother; 2010; 44(7-8):1141-51. PubMed ID: 20587743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous and oral ciprofloxacin treatment of 52 infections.
    Greenberg RN; Wilson KM; Brusca PA
    Am J Med; 1989 Nov; 87(5A):238S-239S. PubMed ID: 2589370
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravenous and sequential intravenous and oral ciprofloxacin in the treatment of severe infections.
    Daly JS; Worthington MG; Razvi SA; Robillard R
    Am J Med; 1989 Nov; 87(5A):232S-234S. PubMed ID: 2589368
    [No Abstract]   [Full Text] [Related]  

  • 16. Sequential intravenous/oral ciprofloxacin as an empiric antimicrobial therapy: results of a Canadian multicenter study. The Canadian Collaborative Investigational Group.
    Davis C
    Clin Ther; 1994; 16(3):505-21. PubMed ID: 7923317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative, double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections.
    Ramirez-Ronda CH; Saavedra S; Rivera-Vázquez CR
    Am J Med; 1987 Apr; 82(4A):220-3. PubMed ID: 3555040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical study of intravenous and oral ciprofloxacin in complicated bacterial infections.
    Gelfand MS; Simmons BP; Craft RB; Grogan JT
    Am J Med; 1989 Nov; 87(5A):235S-237S. PubMed ID: 2589369
    [No Abstract]   [Full Text] [Related]  

  • 19. Unusual case of lymphoedema in a morbidly obese patient.
    Weston S; Clay CD
    Australas J Dermatol; 2007 May; 48(2):115-9. PubMed ID: 17535201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum ciprofloxacin concentrations in patients with severe sepsis being treated with ciprofloxacin 200 mg i.v. bd irrespective of renal function.
    MacGowan AP; White LO; Brown NM; Lovering AM; McMullin CM; Reeves DS
    J Antimicrob Chemother; 1994 May; 33(5):1051-4. PubMed ID: 8089053
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.